These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30062975)

  • 41. Akt Signal Transduction Pathways and Nuclear Factor-kappa B (NF-κB) Transcription as a Molecular Target of Oral Tongue Squamous Cell Carcinoma (SP-C1) Using Papua's Anthill Plant ( Myrmecodia pendans ).
    Achmad H; Supriatno ; Singgih MF; Hendrastuti H
    Pak J Biol Sci; 2016; 19(8-9):323-330. PubMed ID: 29023018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
    Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
    Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor/PI3K/Akt signaling pathway.
    Chien CM; Lin KL; Su JC; Chuang PW; Tseng CH; Chen YL; Chang LS; Lin SR
    Eur J Pharmacol; 2010 Jun; 636(1-3):52-8. PubMed ID: 20371243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
    Wang Q; Zhang X; Song X; Zhang L
    Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Propofol attenuation of hydrogen peroxide-induced injury in human umbilical vein endothelial cells involves aldose reductase.
    Xie CL; Hu LQ; Pan YB; Qian YN
    Pharmazie; 2015 Feb; 70(2):103-9. PubMed ID: 25997250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Limonoids from neem (Azadirachta indica A. Juss.) are potential anticancer drug candidates.
    Nagini S; Palrasu M; Bishayee A
    Med Res Rev; 2024 Mar; 44(2):457-496. PubMed ID: 37589457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
    Hotta N; Kawamori R; Atsumi Y; Baba M; Kishikawa H; Nakamura J; Oikawa S; Yamada N; Yasuda H; Shigeta Y;
    Diabet Med; 2008 Jul; 25(7):818-25. PubMed ID: 18644069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors.
    Kucerova-Chlupacova M; Halakova D; Majekova M; Treml J; Stefek M; Soltesova Prnova M
    Chem Biol Interact; 2020 Dec; 332():109286. PubMed ID: 33038328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular dissection of anti-colon cancer activity of NARI-29: special focus on H
    Np S; Rajdev B; Jain S; Gangasani JK; Vaidya JR; Naidu V
    Free Radic Res; 2023 Apr; 57(4):308-324. PubMed ID: 37523668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Protective effect of epalrestat against high glucose-induced endothelial cell injuries].
    Wang F; Hong Q; Liu G
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(7):940-3. PubMed ID: 22820572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
    Isogai S; Inokuchi T; Ohe K
    Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oenothein B inhibits human non-small cell lung cancer A549 cell proliferation by ROS-mediated PI3K/Akt/NF-κB signaling pathway.
    Pei X; Xiao J; Wei G; Zhang Y; Lin F; Xiong Z; Lu L; Wang X; Pang G; Jiang Y; Jiang L
    Chem Biol Interact; 2019 Jan; 298():112-120. PubMed ID: 30452899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
    Steele JW; Faulds D; Goa KL
    Drugs Aging; 1993; 3(6):532-55. PubMed ID: 8312678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells.
    Zainal NS; Gan CP; Lau BF; Yee PS; Tiong KH; Abdul Rahman ZA; Patel V; Cheong SC
    Phytomedicine; 2018 Jan; 39():33-41. PubMed ID: 29433681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells.
    Pan ST; Qin Y; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1601-26. PubMed ID: 25834400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling.
    Chen HJ; Lin CM; Lee CY; Shih NC; Amagaya S; Lin YC; Yang JS
    Int J Oncol; 2013 Aug; 43(2):629-37. PubMed ID: 23754208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells.
    Ishii H; Tada H; Isogai S
    Diabetologia; 1998 Mar; 41(3):362-4. PubMed ID: 9541179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.